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Abstract
Background: Retinoblastoma (RB) is the most common malignant childhood tumor of the eye and results from
inactivation of both alleles of the RB1 gene. Nowadays RB genetic diagnosis requires classical chromosome
investigations, Multiplex Ligation-dependent Probe Amplification analysis (MLPA) and Sanger sequencing. Nevertheless,
these techniques show some limitations. We report our experience on a cohort of RB patients using a combined
approach of Next-Generation Sequencing (NGS) and RB1 custom array-Comparative Genomic Hybridization (aCGH).
Methods: A total of 65 patients with retinoblastoma were studied: 29 cases of bilateral RB and 36 cases of unilateral
RB. All patients were previously tested with conventional cytogenetics and MLPA techniques. Fifty-three samples were
then analysed using NGS. Eleven cases were analysed by RB1 custom aCGH. One last case was studied only by classic
cytogenetics. Finally, it has been tested, in a lab sensitivity assay, the capability of NGS to detect artificial mosaicism
series in previously recognized samples prepared at 3 different mosaicism frequencies: 10, 5, 1 %.
Results: Of the 29 cases of bilateral RB, 28 resulted positive (96.5 %) to the genetic investigation: 22 point mutations
and 6 genomic rearrangements (four intragenic and two macrodeletion). A novel germline intragenic duplication, from
exon18 to exon 23, was identified in a proband with bilateral RB. Of the 36 available cases of unilateral RB, 8 patients
resulted positive (22 %) to the genetic investigation: 3 patients showed point mutations while 5 carried large deletion.
Finally, we successfully validated, in a lab sensitivity assay, the capability of NGS to accurately measure level of artificial
mosaicism down to 1 %.
Conclusions: NGS and RB1-custom aCGH have demonstrated to be an effective combined approach in order to
optimize the overall diagnostic procedures of RB. Custom aCGH is able to accurately detect genomic rearrangements
allowing the characterization of their extension. NGS is extremely accurate in detecting single nucleotide variants,
relatively simple to perform, cost savings and efficient and has confirmed a high sensitivity and accuracy in identifying
low levels of artificial mosaicisms.
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Background
Retinoblastoma (RB, OMIM:180,200) is the most common
malignant childhood tumor of the eye with an estimated
incidence between 1 in 16,000 and 1 in 18,000 live births
[1, 2]. RB is the first disease for which a genetic etiology of
cancer has been described [3] being caused by mutations
in the first tumor suppressor gene identified (RB1, Gen-
bank accession # L11910). Mutations in both alleles of
the RB1 gene are required for the development of
this neoplasm [4], and, depending on the germ-line
or somatic origin of the defect, a heritable or sporadic
form can be distinguished. RB is unilateral in 60 % of
cases and only 15 % of these are heritable [5]; in contrast,
40 % of retinoblastomas are bilateral with risk of transmis-
sion to the offspring. Heritable retinoblastoma constitutes
a cancer predisposition syndrome [6]. RB1 is located on
chromosome 13 at band q14 and can be affected by a
heterogeneous spectrum of genetic abnormalities, includ-
ing chromosome translocation/deletion, genomic rear-
rangements, ranging from whole gene microdeletion to
intragenic exons loss or duplication, and more than 900
different point mutations [7]. Mutational analysis is per-
formed to search for the predisposing RB1 gene mutation
in peripheral blood of patients with RB, but the mo-
lecular diagnosis requires several technical approaches
to cover the entire field of oncogenic RB1 defects, fre-
quently resulting in numerous, expensive and time con-
suming procedures. In particular, cytogenetic tools, such
as classical chromosome investigations and Fluorescent
In Situ Hybridization (FISH), in addition to Multiplex
Ligation-dependent Probe Amplification (MLPA) tech-
nique, may account for detection of about 16 % of RB1
abnormalities [8], while the remaining large amount of
point mutations need to be investigated using sequencing
analysis. Since the 1970s, Sanger sequencing has been
recognized as the gold standard for mutation analysis in
molecular diagnostics; however, its low-throughput, long
turnaround time and overall cost [9] have called for new
paradigms. Next Generation Sequencing (NGS) can mas-
sively sequence millions of DNA segments, promising low
costs, increased workflow speed and enhanced sensitivity
in mutation detection [9–11]. On the other hand, conven-
tional and molecular cytogenetic analysis, have been re-
placed by modern high-throughput investigations, such as
array Comparative Genomic Hybridization (aCGH), that
can reveal and measure cryptic genomic imbalances. In
addition, aCGH can be focused on specific DNA segments
or genes maximizing the resolution via a customized
process. Based on these observations, we have recruited a
cohort of retinoblastoma patients we previously investi-
gated with conventional cytogenetics and MLPA. Patients
diagnosed with RB but negative to the above standard
screening have been tested with NGS to assess its ability
in identifying RB causative mutations. On the other hand,
patients positive to standard screening have been further
investigated with RB1-custom array CGH analysis to
characterize the genomic rearrangements with a better
resolution compared to the conventional techniques.
Methods
Patient recruitment
In this study we enrolled 65 patients affected by RB from
the Department of Pediatric Hematology-Oncology and
Stem Cell Transplantation of the Bambino Gesù Chil-
dren’s Hospital in Rome. The study was approved by
Ethical committee scientific board of Bambino Gesù Chil-
dren’s Hospital and was conducted in accordance with
the Helsinki Declaration. Blood samples were drawn from
64 patients after obtaining written informed consent from
parents/guardians of affected children. Genomic DNA
was extracted from peripheral blood with Qiagen col-
umns (QIAamp DNA minikit; Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Concentra-
tion and purity of DNA samples were quantified by
ND-1000 spectrophotometer (NanoDrop; Thermo Sci-
entific, Waltham, MA, USA). DNA samples were used
either for NGS or aCGH technique. All 65 patients were
previously tested with conventional cytogenetics and
MLPA techniques. Fifty-three patients, resulted negative
to the first screening, underwent molecular investigation.
Eleven patients, where defects ranging from macroscopic
deletions to intragenic rearrangements have been identi-
fied during the first study, were further characterized by
RB1 custom aCGH. Among these, one patient, positive to
MLPA analysis resulted negative to aCGH. This patient
was then further investigated by single exon conventional
Sanger sequencing. As last, one more patient, positive to
the cytogenetic analysis could not be further studied by
aCGH as no DNA was available at the time of the test
(Table 1).
Targeted re-sequencing
Targeted resequencing was performed with a uniquely
customized design: TruSeq® Custom Amplicon (Illumina,
San Diego, CA) using the MiSeq® sequencing platform
(Illumina). TruSeq Custom Amplicon (TSCA) is a fully
integrated end-to-end amplicon sequencing solution, in-
cluding online probe design and ordering through the
Illumina website, assay, sequencing, automated data ana-
lysis and offline software for reviewing results. Online
probe design was performed by entering into the Design
Studio (DS) software (Illumina) the target genomic regions
[12]. DesignStudio is a personalized, easy-to-use, web-
based sequencing assay design tool that enables to move
from project initiation to design, review, and ordering.
DesignStudio provides dynamic feedback to optimize tar-
get region coverage, reducing the time required to design
custom projects. Once the design is completed, a list of
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amplicons (short regions of DNA covering the full target
region) is visualized and their quality is assessed on the
basis of the predicted amplicon score provided by DS. The
amplicon score is an estimate of the relative performance
of a particular amplicon compared to all others in the
pool. DesignStudio returns only candidate amplicons that
are predicted to work well in the multiplex TruSeq Cus-
tom Amplicon assay. TSCA kit produces the required
targeted amplicons with the necessary adapters and indi-
ces for sequencing on the MiSeq® system without any add-
itional processing. Library preparation and sequencing
runs have been performed according to the manufacturer’s
procedure. Two different TSCA panel designs have been
generated to investigate the same regions of interest for
RB1 gene: promoter, all coding regions, exon-intron
boundaries, 5′UTR and 3′UTR of RB. A first panel of 43
amplicons, each of 250 bp was designed, with a total
length of 5045 bp (Panel A). The total coverage obtained
by DS across the entire region of interest was 97 % with
amplicons showing scores in the range of 60–98 %.
Amplicons with a score lower than 60 % were excluded
from the TSCA panel (3 % of the entire region of interest).
A second panel was designed with amplicons of 425 bp in
length for a total of 36 amplicons (Panel B). In this case,
the predicted coverage of the full region of interest was
100 % with amplicons showing scores in the range of
60–98 %. Of the 53 patients studied with NGS, 48
patients were analyzed using panel A while 5 patients
were analyzed using Panel B.
Mosaicism detection rate assessment
To test the detection rate for mosaic mutations using the
MiSeq, three different types of previously recognized
mutations of RB patients, a substitution, an insertion and
a double deletion, were diluted at different concentrations.
DNA from normal individuals was mixed with the mu-
tated DNA to obtain a final dilution of 10, 5 and 1 %. For
this test all libraries were prepared using the TSCA Panel
B. To compare the most appropriate protocol in terms of
coverage required to discriminate a certain mosaicism
frequency, these samples were sequenced at two different
coverage levels: low coverage (600x) and high coverage
(9000x).
Data analysis
The MiSeq® system provides fully integrated on-instrument
data-analysis software. The MiSeq Reporter software per-
forms secondary analysis on the base calls and quality
scores generated by Real Time Analysis (RTA) during
the sequencing run. The type of analysis performed is
based on the analysis workflow selected. The TruSeq
Amplicon workflow evaluates short regions of ampli-
fied DNA, or amplicons, for variants. The TruSeq Ampli-
con workflow performs demultiplexing of indexed reads,
generates FASTQ files, aligns reads to a reference, identi-
fies variants, and writes output files to the Alignment
folder. SNPs and short indels are identified using the Gen-
ome Analysis Toolkit (GATK). GATK calls raw variants
for each sample, analyzes variants against known variants,
and then calculates a false discovery rate for each variant.
Each single variant has been evaluated for the coverage
and the Qscore, and visualized via Amplicon Viewer (AV)
and Integrative Genome Viewer (IGV) software [13, 14].
The Qscore is the prediction of the probability of an erro-
neous base call, in particular, a value of Q30 represents
the probability to call an erroneous base out of 1000,
reflecting an accuracy of the sequenced base of 99.9 %. All
detected variants have been filtered based on their Qscore:
only variants showing Qscore > 30 have been considered
in this study. Coverage for a defined amplicon is the
average number of sequencing reads representing a given
nucleotide in that amplicon. All mutations identified by
Miseq Reporter were validated by Sanger sequencing
using standard protocols.
RB1 custom array CGH
Array-CGH was carried out using a 60-mer
oligonucleotide-based microarray platform that allows
molecular profiling of genomic aberrations with an over-
all median probe spatial resolution of 41 kb (60 K) (Agi-
lent Technologies Array-CGH Kits, Santa Clara, CA)
with an increased resolution of 1000 times in the cus-
tomized region (88 bp median overall probe spacing)
containing RB1. The design of the custom array slide
was made using the Agilent website dedicated to this
purpose [15]. In order to customize RB1, i.e., to get the
maximum probe coverage of all the exonic and intronic
Table 1 Cohort of patients enrolled in the study and techniques used for their characterization
Cohort Cytogenetic - MLPA technique Samples (technique) Samples (RB) # samples characterized by NGS or aCGH
65 patients 53 negatives 53 (NGS) 22 (BRB) 21
31 (URB) 3
12 positives 11 (aCGH) 6 (BRB) 5
5 (URB) 5
1 - no DNA available 1 (BRB) -
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regions of this gene and its 5′ (1000 bp) and 3′ (500 bp)
segments, we chose all the probes available from Agilent
(2046). Human genomic DNA was used as reference
DNA. Aliquots of 350 ng of DNA from samples were
fragmented with heat for 40 minutes at 99 °C. Then,
each sample was labeled by random priming (Agilent
Technologies) for 2 hours at 37 °C and 10 minutes at
65 °C using Cy5-dUTP for patient DNAs and Cy3-dUTP
for reference DNAs. Labeled products were cleaned-up
with SureTag DNA Labeling Kit Purification Columns
(Agilent Technologies). After probe denaturation for
3 minutes and 30 seconds at 94 °C and pre-annealing
with 2 μg of Cot-1 DNA for 30 minutes at 37 °C,
hybridization was performed at 65 °C with rotation
for 24 hours. After washing steps, following the manu-
facturer’s instructions, the arrays were analyzed using the
Agilent scanner G2505C and Feature Extraction software
v.10.7. A graphical overview of the results was obtained
using Agilent Genomic Workbench v.7.0.
Copy number variations (CNVs) were identified with
the ADM2 (Aberration Detection Method) algorithm and
filtered consulting the Database of Genomic Variants [16].
Results
Of the 65 patients, 64 were investigated either with NGS
or aCGH. Fifty-three patients were analyzed with NGS:
22 were diagnosed with bilateral RB (BRB), while 31 with
the unilateral form (URB). Indeed, 11 patients were
studied with custom aCGH: 6 diagnosed with BRB and 5
with URB.
One last BRB patient, missing DNA for further investi-
gation by aCGH, was analyzed by classic cytogenetics
and showed a large deletion higher than 10 Mb.
NGS
Fifty-three patients were analyzed with NGS in two differ-
ent sequencing runs. Sequencing data generated were
evaluated on the basis of the Qscore and coverage. In the
case of mosaicism experiments, variant frequency was also
evaluated. As predicted by DS coverage indication, Panel
A confirmed coverage of 97 % of the full target region for
all 48 patients studied in this first sequencing run. Exon 2
was only partially sequenced, while exons 14 and 20 were
not sequenced at all. To achieve a full coverage of the
target region, the reported exons had to be investigated by
conventional Sanger sequencing. In the second sequen-
cing run, where Panel B was used, the full target region
(coding regions, promoter and splicing junctions) was
completely sequenced as predicted by DS (100 %). In this
second case, Sanger sequencing was carried-out only to
confirm previously recorded mutations. The mean cover-
age achieved for each sample was 1196 for Panel A and
1309 for Panel B. All detected variants showed a mean
coverage of 592 and a mean Qscore of 39 (99.87 % accur-
acy). An example of performance of Panel B is reported in
Table 2. All but one of the 22 BRB patients have been
Table 2 Coverage level through the target region for patient ID 24 (library preparation performed with Panel B)
Exon Amplicon start Amplicon end Coverage Exon Amplicon start Amplicon end Coverage
5’UTR+1 48877740 48878189 320 17 48955328 48955770 970
48878120 48878544 499 18 49027054 49027468 1800
2 48881319 48881718 750 19 49030255 49030669 635
3 48916666 48917104 1500 20 49033602 49034002 2300
4 48919157 48919573 840 49033928 49034359 3000
5 48921888 48922320 1100 21 49037776 49038175 349
6 48923035 4982348 450 22 49038987 49039397 1300
7 48934082 48934522 2100 23 49039325 49039761 600
8 48936850 18937296 800 24 49047419 49047829 300
9 48938842 48939254 3150 25 49050772 49051184 2900
10 48971551 48941965 3692 26 49051422 49051822 296
11 48942426 48942874 65 27 49053981 49054380 5000
48972798 48943224 135 3’UTR 49054269 49054693 1957
12 48947438 48947854 1371 3’UTR 49051617 49055024 2607
13 48950985 48951409 1500 3’UTR 49054949 49055395 1321
14 48953395 48953828 659 3’UTR 49055319 49055740 2847
48953757 48954206 456 3’UTR 49055661 49056085 428
15-16 48954127 48954562 431 3’UTR 49056009 49056429 2458
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found mutated with NGS. The patient that did not show
any mutation was further analyzed with conventional
Sanger sequencing confirming the absence of any mutation.
Of the 21 identified pathogenic mutations, one was
associated with a rare case of trilateral retinoblastoma.
As regards the 31 URB group, variants have been de-
tected in 3 patients. The features and assortment of all
the mutations found are summarized in Table 3.
CGH array
Eleven patients, showing genomic abnormalities, were
properly characterized in length and position by RB1
custom aCGH analysis (Fig. 1). All five patients with
URB showed only large deletion while in five out six
BRB patients were found three small intragenic dele-
tions, one extended intragenic duplication, unexpectedly
presenting syndromic features, and one large deletion.
The sample found negative by a-CGH was further ana-
lysed by conventional Sanger sequencing focusing on the
same exon recognised as deleted by MLPA. Sanger se-
quencing confirmed the presence of a point mutation.
Genomic rearrangements and their characteristics are
reported in Table 4. In conclusion, the overall number of
RB patients with point mutations or genomic rearrange-
ments identified by either NGS or aCGH was 28 out of
a total of 29 BRB patients (96.5 %) and 8 out of 36 URB
patients (22 %).
Mosaicism detection rate assessment
Dedicated experiments were carried out to investigate the
lowest limit of the NGS method in detecting targeted mu-
tational mosaicism rate. Results are summarized in Table 5.
All variants were correctly identified at each mosaicism
frequency for both sequencing runs (600x and 9000x).
Table 3 List of all mutations identified either by NGS or Sanger sequencing
ID Laterality Exon
intron
Coordinate Type Allele Q Coverage Variant frequency Mutation Protein References
1 TRB 2 48881497 Deletion het 40 446 0.51 c.220_221delGC p.Ala74fs35X New
2 BRB 2 48881523 SNP het 38 167 0.43 c.245C>A p.Ser82X [26]
3 BRB 2 48881542 Deletion het / / / c.264delG Altered splicing New
4 BRB 3 48916744 Insertion het 39 1463 0.5 c.274insT p.Ile92fs109X New
5 BRB 3 48916831 SNP het 38 1409 0.38 c.316C>T p.GLn121X New
6 BRB 3 48916839 Deletion het 37 599 0.51 c.369delAT p.Asn123fs129X New
7 BRB 8 48937069 Deletion het 40 450 0.51 c.837_841delGAACA p.Glu280del_His281X New
8 48937075 Deletion het 40 453 0.51 c.843delG
8 BRB 8 48937095 SNP het 38 250 0.48 c.861+2T>C Altered splicing [29]
9 BRB 10 48941648 SNP het 40 1250 0.49 c.958C>T p.Arge320X [29]
10 BRB 11 489742685 SNP het 39 421 0.52 c.1072C>T p.Arg358X [30]
11 URB IVS-12 48947629 SNP het 39 565 0.52 c.1215+1G>T Altered splicing COSMIC-
COSMIC29786
12a BRB IVS-13 48953729 SNP het / / / c.1333-1G>A Altered splicing [31]
13 BRB 15 48954198 SNP het 37 231 0.47 c.1399C>T p.Arg467X [32]
14 BRB 15 48954198 SNP het 36 343 0.46 c.1399C>T p.Arg467X [32]
15 BRB 18 49027139 SNP het 40 1073 0.49 c.1706T>A p.Leu569X New
16 BRB IVS-19 49033822 SNP het 38 626 0.45 c.1961-2A>G Skip exone 19 [33]
17 BRB IVS-19 49030486 SNP het 39 227 0.45 c.1960+1G>A Altered splicing [34]
18 BRB 20 49033935 Deletion het 39 305 0.47 c.2073delG p.Glu691fs695X New
19 BRB IVS-21 49037976 SNP het 40 593 0.54 c.2211+5G>A Altered splicing [35]
20 BRB 22 49039209 SNP het 40 452 0.45 c.2287A>T p.Arg763X New
21 BRB 23 49039374 SNP het 40 234 0.51 c.2359C>T p.Arg787X [29]
22 URB 23 49039374 SNP het 39 248 0.51 c.2359C>T p.Arg787X [29]
23 BRB 23 49039444 Insertion het 39 860 0.49 c.2429insGTTC p.Lys810fs815X New
24 URB 25 49050852 SNP het 40 960 0.44 c.2536C>T p.Gln846X [26]
25b BRB 7 48934197 Deletion het / / / c.652delT p.Leu218X New
aPatients with mutation detected by Sanger as integration of uncovered regions from Panel A
bPatient negative to array-CGH, re-analysed by Sanger sequencing on the same exon previously identified positive by MLPA
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Only small differences from the expected frequency have
been observed and this could be probably related to the
variability associated to the handling, pipetting and prep-
aration of the dilutions.
For the 1 % mosaicism frequency, it has been evaluated
the frequency of false positive calls in terms of erroneously
called bases in the target site. In details, as regards all
three types of variants studied, the frequency of false posi-
tive events has always been between 0 and 0.02 % for both
sequencing runs. In particular, for the high coverage
sequencing run, the false positive events never exceeded
0.02 %.
Availability of supporting data
The microarray and sequencing raw data are available in
the ArrayExpress database (www.ebi.ac.uk/arrayexpress)
under accession numbers respectively E-MTAB-3492 and
E-M-TAB-3515.
Fig. 1 aCGH profiles of large deletions in patients with URB and TRB
Table 4 List of all genomic rearrangements identified by aCGH or karyotype analysis
ID Laterality Cytogenetics MLPA a-CGH Size
26 TRB 46,XX,del(13)(q14q22) Del whole gene arr 13q13.3q14.3(35,876,405-53,551,359)x1 17.7 Mb
27a BRB 46,XY,del(13)(q13q14) / / >10 Mb
28 BRB 46, XY Dup exon 18 to 23 arr 13q14.2(48,973,699-49,039,548)x3 65.8 Kb
29 BRB 46,XX Del exon 1a-1b arr 13q14.2(48,877,905-48,878,660)x1 755 bp
30 BRB 46,XX Del exon 17 arr 13q14.2(48,954,774-48,955,679)x1 905 bp
31 BRB 46, XY Del exon 3 to 6 arr 13q14.2(48,902,145-48,923,382)x1 21.2 Kb
25b BRB 46, XX Del exon 7 Negative /
32 URB 46,XY,del(13)(q14q22) Del whole gene arr 13q13.3q21.33(38,225,360-72,646,762)x1 34.5 Mb
33 URB 46,XY,del(13)(q14q22) Del whole gene arr 13q14.11q21.33(43,793,461-69,444,583)x1 25.7 Mb
34 URB 46, XY Del whole gene arr 13q14.11q14.2(43,793,461-49,523,881)x1 5.7 Mb
35 URB 46, XY Del whole gene arr 13q14.2(47,343,288-49,047,329)x1 1.74 Mb
36 URB 46, XY Del whole gene arr 13q14.2(47,657,454-49,309,890)x1 1.65 Mb
aGenomic rearrangements detected by karyotype analysis (DNA not available)
bPatient found positive by MLPA, negative by array-CGH, re-analyzed by Sanger method focused on the same exon previously recognized by MLPA as delete
Grotta et al. BMC Cancer  (2015) 15:841 Page 6 of 9
Discussion
The molecular diagnosis of RB is a complex and articu-
late process that still represents an exciting challenge.
Many resources and skills need to be involved to obtain
satisfactory results. High-throughput technologies can
actually offer new opportunities in relation to the amount
of genes potentially analyzed, the number of samples
examined and the quality of results. NGS is an innovative
technology that is able to massive-parallel sequence mil-
lions of DNA segments with high definition capability. It
has a wide diffusion in many fields of biomedical research,
but diagnostic applications for genetic diseases are still in
progress. We report our experience on a cohort of RB
patients using a NGS approach on the Illumina MiSeq
platform. The experiments required different timelines.
The design of the target regions of RB1, carried out using
DS, was performed in few hours. The preparation of
the genomic library using the TSCA Illumina kit, was
completed in two working days. One or two days were
spent to run the samples on the MiSeq (48 samples were
run all together in a first sequencing run using Panel A
and the remaining 5 were run on a second experiment
using Panel B). Few more days were required for results
interpretation of the 53 RB patients using MiSeqReporter,
AV and IGV2.3 software. Furthermore, all mutations iden-
tified by Miseq Reporter, were validated by Sanger sequen-
cing using standard protocols. Of the two panels designed,
Panel B has allowed to reach the full coverage of the target
region, making the standard Sanger sequencing only a tool
for confirming all detected variants. It was also calculated
that the cost of NGS analysis for the entire RB1 gene,
considering comparable devices cost, reagents expenses,
operator’s worktime, would be 7 times less than the
cost of a protocol entirely based on Sanger sequencing,
allowing a strong decrease in costs and a large in-
crease in the number of samples processed for each
experiment [9, 17, 18].
NGS has allowed identifying all variants found in pa-
tients with BRB except one sample in which the variant
was identified neither by Sanger nor by NGS sequencing.
In this case we can speculate that the variant may be
located outside the region under investigation. In fact,
literature data show that 5 % of cases with bilateral in-
volvement may have translocations, deep intronic splice
site mutations, or low-level mosaic mutations, which may
or may not be germline [8]. Twenty-four mutations were
identified in the patients with RB: twelve nonsense, five
frameshift and seven splice site mutations. As expected,
eleven out of the twenty-four mutations found were newly
discovered mutations, never reported before. Among
these a rare case of trilateral RB with a new frameshift
mutation in exon 2 was identified, differently from the
current data reporting macroscopic deletions as the most
frequent defects in this unusual disease [19–22]. The
nonsense mutation p.Arg787X was a known sequence
variation found in the group of URB. The carrier was a
female presenting, at the age of 17 months, with a left eye
RB with loco-regional metastasis also involving lymph-
nodes and bone marrow. She was eye enucleated and
treated with conventional and high-dose chemotherapy,
followed by autologous bone marrow transplantation and
radiotherapy. To date, she is alive and in good clinical
conditions. p.Arg787X is a recurrent mutation commonly
found in BRB as germline sequence variation, while in
URB is more frequent as somatic mutation. Only four
cases of URB carrying this germline mutation have been
Table 5 Artificial mosaicism detection frequencies obtained with NGS experiment (Low coverage sequencing run and high
coverage sequencing run)
ID Mutation type Diluiton (%) Variant Coverage Variant call (%) False positive (%) Variant Coverage Variant call (%) False Positive (%)
22 c.2359C > T 10.00 % 35 7.00 % Not calculated 571 6.00 % Not calculated
5.00 % 24 5.00 % Not calculated 220 4.00 % Not calculated
1.00 % 7 2.00 % 0.00 % 239 2.97 % 0.01 %
ID Mutation type Diluiton (%) Variant Coverage Variant call (%) Error insertions (%) Variant Coverage Variant call (%) Error insertions (%)
4 c.274insT 10.00 % 163 9.00 % Not calculated 2946 10.4 % Not calculated
5.00 % 60 6.25 % Not calculated 707 5.8 % Not calculated
1.00 % 1 2.00 % 0.00 % 9 1.60 % 0.00 %
ID Mutation type Diluiton (%) Variant Coverage Variant call (%) Error deletions (%) Variant Coverage Variant call (%) Error deletions (%)
7 c.837_841delGAACA 10.00 % 35 4.76 % Not calculated 503 6.1 % Not calculated
5.00 % 30 3.6 % Not calculated 298 2.97 % Not calculated
1.00 % 6 0.76 % 0.00 % 51 0.6 % 0.02 %
c.843delG 10.00 % 37 5.00% Not calculated 508 6.1 % Not calculated
5.00 % 31 3.7 % Not calculated 299 2.98 % Not calculated
1.00 % 6 0.76 % 0.00 % 49 0.6 % 0.00 %
Variant call % and error % here reported have been filtered for Qscore > 30
Grotta et al. BMC Cancer  (2015) 15:841 Page 7 of 9
reported [23] including a patient with metastatic presenta-
tion [24]. These findings suggest that the phenotypic
expression of p.Arg787X may reflect the variable pene-
trance of this defect, leading to the different pictures of
the disease. Among the genomic abnormalities identi-
fied with RB1-custom aCGH method, four intragenic
rearrangements and six large deletions involving genes
adjacent to RB1 were revealed. Interestingly, the patients
belonging to the first group had BRB, while the patients of
the second group had mainly URB. These data fortify the
hypothesis that deletion of genes essential for cell survival,
adjacent to RB1, may cause less invasive tumors and,
therefore, result in a higher frequency of unilateral disease
[25, 26]. Patients with deletions greater than 5.7 Mb
showed syndromic features with variable degree of intel-
lectual disability ranging from moderate to severe. Patients
with deletions smaller than 1.74 Mb had only RB. An un-
expected exception was the case of the proband with BRB
carrying an intragenic duplication from exon 18 to 23,
lasting about 66 Kb. This patient presented with a clinical
syndromic picture, characterized by macrosomia, nystag-
mus of the eye, macrocephaly and macroglossia evocative
of the Beckwith-Wiedeman Syndrome. Molecular investi-
gations revealed a normal methylation status and absence
of microdeletions at the locus 11p15.5. Array-CGH did
not show any genomic imbalances. In this cohort, 8 out
36 URB patients resulted positive either to NGS or aCGH,
corresponding to a 22 % frequency. URB mutations are in
fact infrequently found (15 %) in blood circulating cells in
relationship to the known prevalence of somatic mutation
in the target tissue. The 22 % frequency here reported is
slightly different from what is reported in literature, how-
ever, the small number of patients in this cohort is not
enough to establish a significant frequency reference.
Mutational mosaicism is an exciting challenge regarding
molecular diagnostics as well as it is important in the gen-
etic counseling setting. Low levels of mutational mosai-
cism have been identified in probands with bilateral
disease and in individuals with unilateral disease who have
affected children inheriting the mutation [8, 27]. Conven-
tional investigations are unable to routinely detect low-
rate mutated cells: currently, Sanger sequencing is able to
disclose mosaicism only for rates above 20 %. Targeted
mutation analysis is useful to study mosaic recurrent
mutations in blood and can detect DNA variations below
the limit of standard Sanger sequence analysis. This type
of analysis, based on Allele Specific PCR (AS-PCR),
however, investigates, only a limited number of recurrent
point mutations [26]. A more recent study demonstrated
that, using a deep semiconductor sequencing approach
(Ion Torrent, Life Technology), the detection rate of tar-
geted mutational mosaics can be revealed at a frequency
down to 5 % [28]. In our study the capability of NGS in
detecting low mosaicism frequency has been tested. Due
to the absence of patients with RB1 mosaicism, three
previously recognized samples, carriers of single-base sub-
stitution, single-base insertion and a complex rearrange-
ment involving five-base and one-base double deletion
respectively, were diluted with normal DNA at different
concentration (10, 5, 1 %) and tested by NGS with MiSeq
platform. As reported, all three mutations have been
correctly detected at each different frequency for both
coverage levels, independently of the variant type. When
leading studies aimed at identifying low mosaicism fre-
quencies, the major difficulty lies in accurately discrimin-
ating between a somatic variant and a false positive
episode. Based on this, for all three studied mutations, it
has been evaluated the frequency of false positive calls
measured as the percentage of erroneously called bases at
the target site. As shown, for all three types of variants
studied, the frequency of false positive events has always
been between 0 and 0.02 % for both sequencing runs. In
particular, for the high coverage sequencing run, the false
positive events never exceeded 0.02 %, far below the 1 %
mosaicism variant frequency detected. This achievement,
accompanied by a good coverage of the region of interest
can accurately detect low mosaicism frequencies in bio-
logical samples, providing a reliable and sensitive method
of screening. Validation experiments on mosaic biological
samples are currently in progress.
Conclusions
NGS and RB1-custom array CGH demonstrated to be
an effective association in order to optimize the overall
diagnostic procedures of RB. The major advantages pro-
vided by NGS are the high performance capacity and the
elevated accuracy in the data generated. Quality and
quantity of the results acquired in months of traditional
work, are achieved in a single experiment and this con-
tributes to an extraordinary abatement of the global
cost.
NGS has also allowed the identification of artificial
mosaicism frequencies down to 1 %, providing consist-
ent data, high accuracy and extremely low frequency of
false positive events (0.02 %). The possibility to analyze
hundreds of samples per experiment and to sequence
different genes simultaneously makes NGS a powerful
and innovative tool for a modern approach to study rare
diseases.
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